암 환자에서 연수막 전이 진단표지자로서의 뇌척수액 CYFRA 21-1
Cerebrospinal Fluid CYFRA 21-1 as a Diagnostic Indicator for Leptomeningeal Metastasis in Cancer Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The early and accurate diagnosis of leptomeningeal metastasis (LM) has become important because of introduction of new therapeutic strategies for LM and increasing incidence of LM along with longer survival of cancer patients. We aimed to evaluate the role of cerebrospinal fluid (CSF) CYFRA 21-1 as a diagnostic indicator for LM in patients with cancer. Methods: CSF CYFRA 21-1 level was analyzed using electro-chemiluminescent immunoassay. The difference in concentration of CSF CYFRA 21-1 between 91 patients with LM and 339 control groups (patients with other neurological disease or healthy controls) was investigated. The cut-off value of CSF CYFRA 21-1 as a diagnostic indicator for LM and its diagnostic performance were evaluated. Results: The CSF CYFRA 21-1 was significantly higher in LM patients than control groups (p<0.001). A cut-off value of diagnosis for LM in patients with cancer was 1.59 ng/mL. The sensitivity, specificity, accuracy, and positive and negative predictive values of CSF CYFRA 21-1 were 80.2%, 96.2%, 92.8%, 84.9%, 94.8% for diagnosis of LM. Conclusions: These results suggested that CSF CYFRA 21-1 can be an additional diagnostic indicator for cancer patients with LM.
Abstract
Background: The early and accurate diagnosis of leptomeningeal metastasis (LM) has become important because of introduction of new therapeutic strategies for LM and increasing incidence of LM along with longer survival of cancer patients. We aimed to evaluate the role of cerebrospinal fluid (CSF) CYFRA 21-1 as a diagnostic indicator for LM in patients with cancer. Methods: CSF CYFRA 21-1 level was analyzed using electro-chemiluminescent immunoassay. The difference in concentration of CSF CYFRA 21-1 between 91 patients with LM and 339 control groups (patients with other neurological disease or healthy controls) was investigated. The cut-off value of CSF CYFRA 21-1 as a diagnostic indicator for LM and its diagnostic performance were evaluated. Results: The CSF CYFRA 21-1 was significantly higher in LM patients than control groups (p<0.001). A cut-off value of diagnosis for LM in patients with cancer was 1.59 ng/mL. The sensitivity, specificity, accuracy, and positive and negative predictive values of CSF CYFRA 21-1 were 80.2%, 96.2%, 92.8%, 84.9%, 94.8% for diagnosis of LM. Conclusions: These results suggested that CSF CYFRA 21-1 can be an additional diagnostic indicator for cancer patients with LM.
참고문헌 (21)
- Chamberlain MC, "Leptomeningeal metastasis", Curr Opin Oncol, 22, pp.627~635 (2010)
- Groves MD, "New strategies in the management of leptomeningeal metastases", Arch Neurol, 67, pp.305~312 (2010)
- Freilich RJ, "Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis", Ann Neurol, 38, pp.51~57 (1995)
- Hyun JW, "Leptomeningeal metastasis : clinical experience of 519 cases", Eur J Cancer, 56, pp.107~114 (2016)
- Yi HG, "Epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs)are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI", Lung Cancer, 65, pp.80~84 (2009)
- Nakagawa H, "Ventriculolumbar perfusion chemotherapy with methotrexate and cytosine arabinoside for meningeal carcinomatosis : a pilot study in 13patients", Surg Neurol, 45, pp.256~264 (1996)
- Gwak HS, "Ventriculolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis : a phase II study", Oncologist, 19, pp.1044~1045 (2014)
- Barak V, "Clinical utility of cytokeratins as tumor markers", Clin Biochem, 37, pp.529~540 (2004)
- Okamura K, "Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer", Lung Cancer, 80, pp.45~49 (2013)
- Yang DW, "Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients", Cancer, 121(Suppl 17), pp.3113~3121 (2015)
- Barak V, "The diagnostic and prognostic value of tumor markers(CEA, SCC, CYFRA 21-1, TPS)in head and neck cancer patients", Anticancer Res, 35, pp.5519~5524 (2015)
- Chen F, "Diagnostic value of CYFRA 21-1 and carcinoembryonic antigen in diagnosis of operable lung cancer from benign lung disease", J Cancer Res Ther, 14(Supplement), pp.S400~S404 (2018)
- Korkmaz ET, "Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer", Clin Biochem, 58, pp.15~19 (2018)
- Wang P, "The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer", Cancer Biomark, 13, pp.123~130 (2013)
- Zhen Z, "Diagnostic value of CYFRA 21-1 in the cerebrospinal fluid for leptomeningeal metastasis", Dis Markers, 2017, pp.2467870~ (2017)
- Hyun JW, "Diagnostic and prognostic values of cerebrospinal fluid CYFRA 21-1 in patients with leptomeningeal carcinomatosis", Oncotarget, 8, pp.53326~53335 (2017)
- Forster RJ, "Electrogenerated chemiluminescence", Annu Rev Anal Chem(Palo Alto Calif), 2, pp.359~385 (2009)
- Zhao B, "Establishment of reference interval for the tumour marker serum CYFRA 21-1 in healthy Chinese Han ethnic adults", Scand J Clin Lab Invest, 78, pp.171~174 (2018)
- Glass JP, "Malignant cells in cerebrospinal fluid(CSF) : the meaning of a positive CSF cytology", Neurology, 29, pp.1369~1375 (1979)
- Nabors LB, "Central nervous system cancers, version 1.2015", J Natl Compr Canc Netw, 13, pp.1191~1202 (2015)
- Gorson KC, "Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barrésyndrome", Neurology, 47, pp.813~817 (1996)